Login to Your Account



Series A Finishes with $8M

Epitope Hope: Dengue, Flu May Succumb to Visterra Approach

By Randy Osborne
Staff Writer

Wednesday, November 27, 2013
Visterra Inc.’s $8.1 million in proceeds from its upsized Series A round gives the company enough cash to finish Phase I trials with its influenza drug and choose a lead candidate for advancement against dengue fever. “It’s a tranched financing, so we’ve been spending the money right along,” said Brian Pereira, president and CEO of Cambridge, Mass.-based Visterra, founded four years ago. The name of the company, with 27 full-time employees, means “vision of the earth.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription